Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Basic & Clinical Pharmacology & Toxicology|January 1, 2010
Variability and impact on design of bioequivalence studiesAchiel Van Peer
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 11, 2016
Use of physiologically relevant biopharmaceutics tools within the pharmaceutical industry and in regulatory sciences: Where are we now and what are the gaps?Talia Flanagan, Achiel Van Peer, Anders Lindahl
Expert Opinion on Drug Metabolism & Toxicology|February 13, 2014
The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvementItalo Poggesi, Jan Snoeys, Achiel Van Peer
Clinical Pharmacology in Drug Development|May 4, 2016
Single-Dose Pharmacokinetic Study of Tramadol Extended-Release Tablets in Children and AdolescentsJoris Vandenbossche, Achiel Van Peer, Henry Richards
Pharmaceutical Research|October 23, 2009
Physiologically-based PK/PD modelling of therapeutic macromoleculesPeter Thygesen, Panos Macheras, Achiel Van Peer
Pharmaceutical Research|June 14, 2008
Bioavailability and bioequivalence: focus on physiological factors and variabilityVangelis Karalis, Panos Macheras, Achiel Van Peer, et al.
Journal of Clinical Pharmacology|May 20, 2003
Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulationsVladimir Piotrovsky, Achiel Van Peer, Nancy Van Osselaer, et al.
Pharmaceutical Research|July 19, 2008
Including information on the therapeutic window in bioequivalence acceptanceTom Jacobs, Filip De Ridder, Sarah Rusch, et al.
Biopharmaceutics & Drug Disposition|March 3, 2012
From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case exampleVikash Kumar Sinha, Jan Snoeys, Nancy Van Osselaer, et al.
Journal of Clinical Pharmacology|September 5, 2002
Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjectsQinying Zhao, Martin Brett, Nancy Van Osselaer, et al.
Pageof 3